FR2437838A1 - Medicament pour le traitement de l'adenome benin de la prostate - Google Patents

Medicament pour le traitement de l'adenome benin de la prostate

Info

Publication number
FR2437838A1
FR2437838A1 FR7823535A FR7823535A FR2437838A1 FR 2437838 A1 FR2437838 A1 FR 2437838A1 FR 7823535 A FR7823535 A FR 7823535A FR 7823535 A FR7823535 A FR 7823535A FR 2437838 A1 FR2437838 A1 FR 2437838A1
Authority
FR
France
Prior art keywords
acid
derivs
pyrrole
anthranilic
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7823535A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roecar Holdings NV
Original Assignee
Roecar Holdings NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roecar Holdings NV filed Critical Roecar Holdings NV
Publication of FR2437838A1 publication Critical patent/FR2437838A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

LA PRESENTE INVENTION CONCERNE UN MEDICAMENT POUR LE TRAITEMENT DE L'ADENOME BENIN DE LA PROSTATE. LE MEDICAMENT SELON L'INVENTION CONTIENT DES COMPOSES AYANT UNE ACTION DE DIMINUTION OU DE NORMALISATION LENTE DU TAUX DE PROSTAGLANDINES DU TISSU. CES COMPOSES PEUVENT DONC ETRE PAR EXEMPLE DES DERIVES DE L'ACIDE SALICYLIQUE, DES DERIVES DE L'ACIDE ANTHRANILIQUE, DES DERIVES DE L'ACIDE PHENYLACETIQUE, DES DERIVES DU PYRROLE ET DE LA PYRAZOLIDINE, DES DERIVES DE L'INDOLE OU PEUVENT APPARTENIR A DIVERS CLASSES DE SUBSTANCES CHIMIQUES.
FR7823535A 1978-07-25 1978-08-09 Medicament pour le traitement de l'adenome benin de la prostate Withdrawn FR2437838A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2832531 1978-07-25

Publications (1)

Publication Number Publication Date
FR2437838A1 true FR2437838A1 (fr) 1980-04-30

Family

ID=6045290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7823535A Withdrawn FR2437838A1 (fr) 1978-07-25 1978-08-09 Medicament pour le traitement de l'adenome benin de la prostate

Country Status (1)

Country Link
FR (1) FR2437838A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003442A1 (fr) * 1983-03-11 1984-09-13 Biogal Gyogyszergyar Compositions pharmaceutiques ayant un effet anti-inflammatoire sur le pancreas
WO2001028566A1 (fr) * 1999-10-19 2001-04-26 Instituto Helmaprost, S.L. Utilisation de l'acide acetyl salicilique dans le traitement de l'hyperplasie de la prostate benigne
WO2001030324A2 (fr) * 1999-10-27 2001-05-03 Aufsess Joachim G Utilisation d'acide acetylsalicylique et preparation pour traiter l'hyperplasie prostatique
WO2004089379A2 (fr) * 2003-04-07 2004-10-21 Boehringer Ingelheim International Gmbh Combinaison pharmaceutique pour traiter l'hyperplasie prostatique benigne ou la prostatite abacterienne
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9993557B2 (en) 2000-06-20 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003442A1 (fr) * 1983-03-11 1984-09-13 Biogal Gyogyszergyar Compositions pharmaceutiques ayant un effet anti-inflammatoire sur le pancreas
WO2001028566A1 (fr) * 1999-10-19 2001-04-26 Instituto Helmaprost, S.L. Utilisation de l'acide acetyl salicilique dans le traitement de l'hyperplasie de la prostate benigne
WO2001030324A2 (fr) * 1999-10-27 2001-05-03 Aufsess Joachim G Utilisation d'acide acetylsalicylique et preparation pour traiter l'hyperplasie prostatique
WO2001030324A3 (fr) * 1999-10-27 2001-11-22 Joachim G Aufsess Utilisation d'acide acetylsalicylique et preparation pour traiter l'hyperplasie prostatique
US9993557B2 (en) 2000-06-20 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US10098891B2 (en) 2001-12-12 2018-10-16 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
WO2004089379A2 (fr) * 2003-04-07 2004-10-21 Boehringer Ingelheim International Gmbh Combinaison pharmaceutique pour traiter l'hyperplasie prostatique benigne ou la prostatite abacterienne
WO2004089379A3 (fr) * 2003-04-07 2005-01-13 Boehringer Ingelheim Int Combinaison pharmaceutique pour traiter l'hyperplasie prostatique benigne ou la prostatite abacterienne
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US9186296B2 (en) 2009-10-12 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9943486B2 (en) 2010-05-05 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Similar Documents

Publication Publication Date Title
FR2437838A1 (fr) Medicament pour le traitement de l'adenome benin de la prostate
McCracken A two-part model of stimulant action on attention-deficit hyperactivity disorder in children.
US4593044B1 (fr)
Riendeau et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor
GB8521350D0 (en) Analgesic composition
IL95721A0 (en) Oral anticoagulant/platelet inhibitor low dose formulation
NO923859L (no) Medikament
Matsushita et al. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats
ES8102153A1 (es) Metodo para preparar un derivado inmuno-regulador de un co- polimero
JPS542340A (en) Antiinflammatory composition containing salycilic acid
ES410559A1 (es) Un metodo de preparar 1-(cremoniloxi sustituido en posicion2)-2-hidroxi-3-(fenoxi sustituidos propamen).
ES8800903A1 (es) Un procedimiento para preparar indol-alfa-ceto-acidos y sus esteres.
Khan et al. COX‐2 inhibitors for endodontic pain
ES2164849T3 (es) Soluciones acuosas con sabor enmascarado que contienen ibuprofeno y mentol.
Chan et al. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases
Tey et al. Acitretin induced bipedal edema
Kim et al. Laparoscopic resection of hepatic tumor using a gasless technique
Garnett Strong medicine.
Church et al. Unions arise--with new tricks.
Jones Banishing the magicians.
EP0748627A3 (fr) Agonistes de la mélatonine pour l'utilisation dans le traitement d'hyperplasies prostatiques bénignes
Daldry Our theatres are being turned into Thistle Hotels--great for a drink, useless for art--thanks to...
JPS5673600A (en) Preventing method of scale in water
Royanov Mechanized oxygen-arc cutting of cast-iron pipes of water mains under field conditions
Pooley Nuclear safety fallout.

Legal Events

Date Code Title Description
ST Notification of lapse